zoledronic acid has been researched along with Multiple Primary Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Agrillo, A; Corsi, A; Riminucci, M; Ungari, C | 1 |
Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
2 other study(ies) available for zoledronic acid and Multiple Primary Neoplasms
Article | Year |
---|---|
Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw.
Topics: Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Neoplasms; Breast Neoplasms; Diagnosis, Differential; Diphosphonates; Fatal Outcome; Female; Fractures, Spontaneous; Humans; Imidazoles; Infusions, Intravenous; Mandible; Mandibular Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Radiography, Panoramic; Tomography, X-Ray Computed; Zoledronic Acid | 2017 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |